NCT03643913View on ClinicalTrials.gov

The Effect of Deep Neuromuscular Block and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Shoulder Surgery Using a Deltopectoral Approach

PHASE4CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 18, 2018

Primary Completion Date

November 27, 2024

Study Completion Date

November 27, 2024

Conditions
Shoulder PainAnesthesia
Interventions
PROCEDURE

Deep neuromuscular block

Deep neuromuscular block requiring higher doses of Esmeron to target a post tetanic count (PTC) of 1-2 and higher doses of Bridion to reverse the block (4mg/kg).

PROCEDURE

Moderate neuromuscular block

Normal neuromuscular block requiring dosis of Esmeron to target a train of four (TOF) count of max 2 and lower doses of Bridion to reverse the block (2mg/kg).

DRUG

Neuromuscular Blocking Agents and reversing agents

Deep neuromuscular block versus moderate neuromuscular block.

Trial Locations (1)

3000

University Hospitals Leuven, Leuven

All Listed Sponsors
collaborator

MSD Belgium BVBA

INDUSTRY

lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT03643913 - The Effect of Deep Neuromuscular Block and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Shoulder Surgery Using a Deltopectoral Approach | Biotech Hunter | Biotech Hunter